NYSE · MDT
Medtronic Plc
$97.11+$2.33 (+2.46%)
Medtronic Plc’s quoted price sits in the upper half of its reported 52-week range, 8.67% below the high.
Loading market information…
NASDAQ · ALKS · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Alkermes plc’s quoted price sits in the upper half of its reported 52-week range, 18.5% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Alkermes plc’s next earnings report is currently expected on Nov 3, 2026, with estimated earnings per share of -$0.08. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Alkermes plc’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and LUMRYZ, an extended-release oral suspension product for the treatment of cataplexy or EDS in pediatric patients. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 02:31 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q1 2025 |
|---|
| May 1, 2025 |
| $0.13-48.92% vs estimate |
| $306.51M+1.19% vs estimate |
| Q4 2024 | Feb 12, 2025 | $1.04+28.4% vs estimate | $429.99M+13.33% vs estimate |
|---|
| Q3 2024 | Oct 24, 2024 | $0.72-2.7% vs estimate | $378.14M-0.84% vs estimate |
|---|
THE ANALYST VIEW
29 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Consensus coverage: 7 contributors · Median target $56.00.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$97.11+$2.33 (+2.46%)
Medtronic Plc’s quoted price sits in the upper half of its reported 52-week range, 8.67% below the high.
$215.48+$1.32 (+0.62%)
ICON Public Limited Company’s quoted price sits in the upper half of its reported 52-week range, 1.61% below the high.
$146.38+$0.85 (+0.58%)
Neurocrine Biosciences, Inc.’s quoted price sits in the lower half of its reported 52-week range, 21.35% below the high.
$207.83+$2.77 (+1.35%)
Jazz Pharmaceuticals plc’s quoted price sits in the upper half of its reported 52-week range, 21.98% below the high.
$143.45-$0.06 (-0.04%)
Axsome Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 44.87% below the high.
$20.76+$0.44 (+2.17%)
Acadia Pharmaceuticals Inc.’s quoted price sits in the lower half of its reported 52-week range, 32.95% below the high.
$41.84+$0.76 (+1.85%)
Supernus Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 29.89% below the high.
$4.05+$0.05 (+1.25%)
Vanda Pharmaceuticals Inc.’s quoted price sits in the lower half of its reported 52-week range, 59.26% below the high.
